Resources

Once daily glimepiride dosages provide effective glycemic control and result in weight neutralizing or reducing effects in patients with Type 2 diabetes.

First prospective intervention study testing the postprandial hyperglycemia hypotheses as a risk factor for cardiovascular disease. “Acarbose treatment was associated with a relative risk reduction of 49% for cardiovascular events.

In a study of more than 4000 subjects, elevated cholesterol levels were found to be associated with an increased risk of renal dysfunction in apparently healthy men

Findings provide strong support for aggressive BP reduction for people with nephropathy from type 2 diabetes.

Angiotensin-converting enzyme (ACE) inhibitors improve markers of cardiovascular disease and prevent diabetes, renal disease, and cardiovascular disease.

First randomised trial ever to report that people who have a high risk of developing type 2 diabetes mellitus can prevent the disease.

New Protein Identified Which Can Possibly Unlock The Treatment For Obesity

Patients who received repaglinide/metformin treatment had lower final HbA1c values than those who received nateglinide/metformin.

New study findings indicate that replenishment of this hormone with supplements can improve endothelial function and insulin sensitivity-which may lower the risk of heart disease.

Glucosamine supplementation does not cause clinically significant changes in glucose metabolism in patients with type 2 diabetes.